I agree that this site is using cookies. You can find further informations here.
X
Samineni, Divya
39  results:
Search for persons X
?
1

Clinical pharmacology strategies to accelerate the developm..:

Liao, Michael Z. ; Lu, Dan ; Lu, Tong...
Advanced Drug Delivery Reviews.  207 (2024)  - p. 115193 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Dose Optimization in Oncology Drug Development: An Internat..:

Samineni, Divya ; Venkatakrishnan, Karthik ; Othman, Ahmed A....
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
3

Pharmacokinetics and Exposure-Response Analysis of Venetocl..:

Samineni, Divya ; Gibiansky, Leonid ; Wang, Bei...
Advances in Therapy.  39 (2022)  8 - p. 3635-3653 , 2022
Link: https://doi.org/10.1007/..
 
?
4

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients wi..:

Herrera, Alex F. ; Patel, Manish R. ; Burke, John M....
Clinical Cancer Research.  28 (2022)  7 - p. 1294-1301 , 2022
Link: https://doi.org/10.1158/..
 
?
5

Bioavailability Evaluation of Venetoclax Lower-Strength Tab..:

Badawi, Mohamed ; Chen, Xin ; Marroum, Patrick...
Clinical Drug Investigation.  42 (2022)  8 - p. 657-668 , 2022
Link: https://doi.org/10.1007/..
 
?
6

Population Pharmacokinetics and Exposure–Response Analyses ..:

Samineni, Divya ; Huang, Weize ; Gibiansky, Leonid...
Advances in Therapy.  39 (2021)  1 - p. 598-618 , 2021
Link: https://doi.org/10.1007/..
 
?
7

Model‐Informed Therapeutic Dose Optimization Strategies for..:

Liao, Michael Z. ; Lu, Dan ; Kågedal, Matts...
Clinical Pharmacology & Therapeutics.  110 (2021)  5 - p. 1216-1230 , 2021
Link: https://doi.org/10.1002/..
 
?
8

A Phase I dose‐escalation study of DCLL9718S, an antibody‐d..:

Daver, Naval ; Salhotra, Amandeep ; Brandwein, Joseph M....
American Journal of Hematology.  96 (2021)  5 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

Physiologically Based Pharmacokinetic Model‐Informed Drug D..:

Samineni, Divya ; Ding, Hao ; Ma, Fang...
The Journal of Clinical Pharmacology.  60 (2020)  S1 - p. , 2020
Link: https://doi.org/10.1002/..
 
?
10

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifas..:

Moore, Kathleen N. ; Birrer, Michael J. ; Marsters, Jim...
Gynecologic Oncology.  158 (2020)  3 - p. 631-639 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Impact of Physiologically Based Pharmacokinetics, Populatio..:

Li, Chunze ; Chen, Shang‐Chiung ; Chen, Yuan...
The Journal of Clinical Pharmacology.  60 (2020)  S1 - p. , 2020
Link: https://doi.org/10.1002/..
 
?
12

Time‐to‐Event Modeling of Peripheral Neuropathy: Platform A..:

Kågedal, Matts ; Samineni, Divya ; Gillespie, William R....
CPT: Pharmacometrics & Systems Pharmacology.  8 (2019)  8 - p. 606-615 , 2019
Link: https://doi.org/10.1002/..
 
?
13

Prediction of Human Pharmacokinetics of Antibody–Drug Conju..:

Li, Chunze ; Zhang, Cindy ; Deng, Rong...
Clinical and Translational Science.  12 (2019)  5 - p. 534-544 , 2019
Link: https://doi.org/10.1111/..
 
?
14

Clinical pharmacology of vc-MMAE antibody–drug conjugates i..:

Li, Chunze ; Zhang, Cindy ; Li, Zao...
mAbs.  12 (2019)  1 - p. , 2019
Link: https://doi.org/10.1080/..
 
?
15

Phase I study of the anti-FcRH5 antibody-drug conjugate DFR..:

Stewart, A. Keith ; Krishnan, Amrita Y. ; Singhal, Seema...
Blood Cancer Journal.  9 (2019)  2 - p. , 2019
Link: https://doi.org/10.1038/..
 
1-15